Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Pollak

Showing results (31-40 of 236) with videos related to

Pageof 24
Sort By:
Growth Factors (Chur, Switzerland)|April 8, 2010
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcriptionMatei Mireuta, Andrew Darnel, Michael Pollak
The Journal of Biological Chemistry|March 11, 2011
Binding between insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 is not influenced by glucose or 2-deoxy-D-glucoseMatei Mireuta, Mark A Hancock, Michael Pollak
JAMA Oncology|July 17, 2015
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate CancerLaurent Azoulay, Maria Eberg, Serge Benayoun, et al.
Biochemical and Biophysical Research Communications|December 31, 2003
Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cellsYuhong Lu, Xiaolin Zi, Yunhua Zhao, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2009
Current status and challenges associated with targeting mTOR for cancer therapyRyan J O Dowling, Michael Pollak, Nahum Sonenberg
Biochemical and Biophysical Research Communications|September 13, 2005
PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2Randy J Levitt, Maria-Magdalena Georgescu, Michael Pollak
Breast Cancer Research : BCR|May 13, 2008
Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional studyCaroline Diorio, Jacques Brisson, Sylvie Bérubé, et al.
Breast Cancer Research : BCR|July 1, 2005
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsAnne Camirand, Mahvash Zakikhani, Fiona Young, et al.
Endocrinology|January 16, 2014
Quantification of binding of IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 miceMatei Mireuta, Elena Birman, Melinda Barmash, et al.
Journal of Molecular Endocrinology|August 4, 2018
Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasiaOro Uchenunu, Michael Pollak, Ivan Topisirovic, et al.
Pageof 24

Showing results (31-40 of 236) with videos related to

Sort By:
Pageof 24
Growth Factors (Chur, Switzerland)|April 8, 2010
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcriptionMatei Mireuta, Andrew Darnel, Michael Pollak
The Journal of Biological Chemistry|March 11, 2011
Binding between insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 is not influenced by glucose or 2-deoxy-D-glucoseMatei Mireuta, Mark A Hancock, Michael Pollak
JAMA Oncology|July 17, 2015
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate CancerLaurent Azoulay, Maria Eberg, Serge Benayoun, et al.
Biochemical and Biophysical Research Communications|December 31, 2003
Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cellsYuhong Lu, Xiaolin Zi, Yunhua Zhao, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2009
Current status and challenges associated with targeting mTOR for cancer therapyRyan J O Dowling, Michael Pollak, Nahum Sonenberg
Biochemical and Biophysical Research Communications|September 13, 2005
PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2Randy J Levitt, Maria-Magdalena Georgescu, Michael Pollak
Breast Cancer Research : BCR|May 13, 2008
Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional studyCaroline Diorio, Jacques Brisson, Sylvie Bérubé, et al.
Breast Cancer Research : BCR|July 1, 2005
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsAnne Camirand, Mahvash Zakikhani, Fiona Young, et al.
Endocrinology|January 16, 2014
Quantification of binding of IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 miceMatei Mireuta, Elena Birman, Melinda Barmash, et al.
Journal of Molecular Endocrinology|August 4, 2018
Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasiaOro Uchenunu, Michael Pollak, Ivan Topisirovic, et al.
Pageof 24